The trial will be a multi-center, open-label study involving 75 patients and evaluating multiple INF904 dosing ... data and provide signs of clinical benefit, and to inform the design of a Phase 2b ...
Q3 2024 Earnings Call Transcript November 5, 2024 Rhythm Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.8. Operator: Good day, and thank you for ...